KAYAHAN SATİŞ, N. Et Al. 2018. FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER. 2 nd International Congress on Oncological Sciences .

KAYAHAN SATİŞ, N., ÖZET, A., SATİŞ, H., & KARACA, M., (2018). FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER . 2 nd International Congress on Oncological Sciences

KAYAHAN SATİŞ, NESLİHAN Et Al. "FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER," 2 nd International Congress on Oncological Sciences, 2018

KAYAHAN SATİŞ, NESLİHAN K. Et Al. "FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER." 2 nd International Congress on Oncological Sciences , 2018

KAYAHAN SATİŞ, N. Et Al. (2018) . "FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER." 2 nd International Congress on Oncological Sciences .

@conferencepaper{conferencepaper, author={NESLİHAN KAYAHAN SATİŞ Et Al. }, title={FOLFIRINOX VERSUS GEMCITABINE-CYSPLATINCOMBINATION AS FIRST LINE THERAPY IN TREATMENTOF PANCREATICOBILIARY CANCER}, congress name={2 nd International Congress on Oncological Sciences}, city={}, country={}, year={2018}}